Anthem Biosciences IPO — Should You Subscribe Or Not? Read Anand Rathi's Report

The Rs 3,395 crore IPO, comprises entirely of an offer-for-sale component of 5.96 crore shares. Anthem Biosciences Ltd. is set to launch its IPO on July 14 and the offer closes for subscription on July 16..NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Anand Rathi Report.Anthem Biosciences Ltd. is set to launch its IPO on July 14 and the offer closes for subscription on July 16. Anthem Biosciences is a fully integrated, innovation-led and technology-driven CRDMO offering end-to-end solutions across the drug discovery, development, and manufacturing value chain.The company has fixed the price band in the range of Rs 540 to Rs 570 per share.The Rs 3,395 crore IPO, comprises entirely of an offer-for-sale component of 5.96 crore shares.Investors can place bids starting from a minimum of 26 shares and in multiples thereafter.Since the Anthem Biosciences IPO is entirely an OFS, proceeds from the offer will go directly to the selling shareholders. JM Financial Ltd., Citigroup Global Markets India Pvt Ltd, J.P. Morgan India Pvt Ltd, Nomura Financial Advisory and Securities (India) Pvt Ltd. are the book-running lead managers for the public issue..Valuation and outlookAnthem biosciences is well positioned to cater in CROs and CRDMO segment the crucial players in the pharmaceutical and biotechnology industries wherein the company being niche player in with high entry barriers through its differentiated FFS model, long term relationship, strong R&D, innovation and technology driven approach across drug discovery, development and manufacturing. The company has shown profitable track record against its peers and intend to maintain it be leveraging its integrated manufacturing and technological capabilities by focusing on building complex speciality ingredients, peptides, probiotics etc. On valuation parse, based on annualised FY25 it is seeking PE of 70.6 times, and post issue market cap comes at Rs 3,18,673 million with this the issue is fairly priced. We believe company has potential to continue to grow its revenue and profitability ratios compared to its peers. Hence, we give “Subscribe” rating for the issue..Key RisksDependence on CRDMO Business: The company revenue is significantly dependent on demand for our CRDMO services, which accounted for 81.65% of our operational revenue in Fiscal 2025. Any adverse developments affecting their CRDMO customers or the sectors they operate in could materially impact its business performance, financial condition, and growth prospects. Major reliance on Developmental and Commercial Manufacturing: In Fiscal 2025, developmental and commercial manufacturing accounted for 70.78% of revenue from operations and 71.90% of total project portfolio. Any setbacks in early-phase development or failure to successfully advance or manufacture commercially viable drug candidates whether due to scientific, regulatory, or external market factors beyond their control could adversely impact our revenue, project pipeline, and overall business performance. Regulatory Compliance Risk: The Company operates in a highly regulated environment and is subject to extensive statutory and regulatory requirements. Failure to obtain, maintain, or timely renew the necessary licenses, permits, and approvals could disrupt operations and have a material adverse impact on business continuity, financial performance, and cash flows.Patent Expiry Risk: The Company is exposed to the risk of revenue loss from manufacturing services provided to innovator pharmaceutical companies following the expiry of their patent protection. Post-patent expiry, lower-cost generic alternatives may enter the market, potentially reducing demand for the company’s services related to those original formulations.Regulatory Inspection and Approval Risk: The Company’s manufacturing facilities are subject to regular audits and inspections by regulatory authorities and clients. Any delay or failure in obtaining necessary approvals or clearances could adversely impact operational continuity, customer relationships, and may have a material effect on the company’s financial performance and cash flows..Click on the attachment to read the full report:.'Buy' Suzlon Energy Shares To Get An Upside Of 24% Says Motilal Oswal — Here's Why .DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Anthem Biosciences IPO — Should You Subscribe Or Not? Read Anand Rathi's Report

The Rs 3,395-crore IPO will launch on July 14 for subscription and the company has fixed the price band in the range of Rs 540 to Rs 570 per share.

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

Anthem Biosciences IPO — Should You Subscribe Or Not? Read Anand Rathi's Report

The Rs 3,395-crore IPO will launch on July 14 for subscription and the company has fixed the price band in the range of Rs 540 to Rs 570 per share.

Choose a plan

Follow Us

DOWNLOAD THE APP